IDiyas

For the Inventor, By the Inventor

Wuppertal-Elberfeld, Germany

Friedrich Hoffmeister

USPTO Granted Patents = 12

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 384(Granted Patents)


Location History:

  • Wuppertal-Elberfeld, DE (1976 - 1977)
  • Wuppertal, DE (1976 - 1987)

Company Filing History:

goldMedal12 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1976-1987

Loading Chart...
12 patents (USPTO):Explore Patents
1. 4657924 - Nafazatrom as a lipoxygenase inhibitor (1987-04-14),
2. 4552874 - Pyrazolooxazines, pyrazolothiazines, and pryazoloquinolines and their (1985-11-12),
3. 4540707 - Nafazatrom as a lipoxygenase inhibitor (1985-09-10),
4. 4406906 - Cerebral therapeutic agent and its use (1983-09-27),
5. 4187306 - Benzodiazepine-diones, a process for their production and their use as (1980-02-05),
6. 4110472 - Derivatives of 1-(disubstituted phenoxy)-3-amino-2-hydroxypropanes (1978-08-29),
7. 4070494 - Enteral pharmaceutical compositions (1978-01-24),
8. 4065568 - 3-Carbo(lower alkoxy)hydrazinoindazoles (1977-12-27),
9. 4051252 - 3-Aminoindazole-1 and 2-carboxylic acid derivatives (1977-09-27),
10. 3989844 - Basic oximes and their preparation (1976-11-02),
11. 3963778 - Basic oximes and their preparation (1976-06-15),
12. 3936463 - Benzomorphanes (1976-02-03),

Title: Friedrich Hoffmeister: Innovator in Lipoxygenase Inhibition

Introduction

Friedrich Hoffmeister, an accomplished inventor located in Wuppertal-Elberfeld, Germany, has made significant contributions to the field of pharmacology. With a portfolio of 12 patents, Hoffmeister has focused his research on developing innovative compounds that target specific medical conditions, particularly through the inhibition of lipoxygenase.

Latest Patents

Among his latest inventions, one of his notable patents is for Nafazatrom, a lipoxygenase inhibitor. This method is designed for the prophylaxis and treatment of various conditions, including ischaemias, cardiac rhythm disorders, rheumatic diseases, allergies, asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications, and ulcerations. The approach involves administering an effective amount of Nafazatrom to patients suffering from these ailments.

Another significant invention from Hoffmeister is related to pyrazolooxazines, pyrazolothiazines, and pyrazoloquinolines, defined by Formula I. This invention encompasses not only the compounds themselves but also includes compositions that utilize these compounds for their lipoxygenase-inhibiting properties. Additionally, methods for manufacturing these compounds are elaborated upon in his patent filings.

Career Highlights

Hoffmeister is associated with Bayer Aktiengesellschaft, a leading global enterprise in pharmaceuticals and life sciences. His work has directly impacted the development of medications that improve health outcomes for patients with various complex disorders. His research within Bayer supports the company's commitment to innovation and excellence in healthcare.

Collaborations

Throughout his career, Hoffmeister has collaborated with prominent colleagues, including Karl Heinrich Mayer and Mithat Mardin. Together, they have advanced research and development initiatives, fostering a dynamic environment that encourages creativity and innovation in pharmaceutical sciences.

Conclusion

Friedrich Hoffmeister stands out as a prominent inventor dedicated to enhancing medical treatments through innovative compounds. His contributions to lipoxygenase inhibition reflect his commitment to improving patient lives through scientific discovery. As he continues to push the boundaries of pharmacological research, Hoffmeister remains a key figure in the evolving landscape of modern medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…